HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt.

Abstract
The synthesis from l-quebrachitol of a series of 3-deoxygenated ether lipid-type phosphatidylinositol (PI) analogues is reported, that selectively block activation of Akt and downstream substrates without affecting activation of the upstream kinase, PDK-1, or other kinases downstream of ras such as MAPK in H157 and H1703 lung cancer cells that have high levels of constitutively active Akt. The 2-hydroxyl in these compounds was deleted or alkylated with the intent to preclude metabolic degradation of these compounds by PI-specific phospholipase C (PI-PLC). PI analogues with phosphate linkers are more effective than those with carbonate linkers. Specific inhibition of Akt by these compounds validates ligand design targeted to the PH domains of crucial signaling proteins, thus providing a unique class of possible cancer therapeutics.
AuthorsAlan P Kozikowski, Haiying Sun, John Brognard, Phillip A Dennis
JournalJournal of the American Chemical Society (J Am Chem Soc) Vol. 125 Issue 5 Pg. 1144-5 (Feb 05 2003) ISSN: 0002-7863 [Print] United States
PMID12553797 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Enzyme Inhibitors
  • Phosphatidylinositols
  • Proto-Oncogene Proteins
  • AKT1 protein, human
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
Topics
  • Enzyme Activation (drug effects)
  • Enzyme Inhibitors (chemical synthesis, pharmacology)
  • Humans
  • Lung Neoplasms (enzymology)
  • Phosphatidylinositols (chemical synthesis, pharmacology)
  • Phosphorylation (drug effects)
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins (antagonists & inhibitors, metabolism)
  • Proto-Oncogene Proteins c-akt
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: